See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements
Sequoia Pharmaceuticals Announces Appointment of Steven D. Skolsky as Chief Executive Officer
GAITHERSBURG, Md., Oct. 29 /PRNewswire/ -- Sequoia Pharmaceuticals,
Inc., which discovers and develops novel antiviral therapeutics as well as
pharmacokinetic enhancers, announced today the appointment of Steven D.
Skolsky as its President and Chief Executive Officer. He will also serve as
a member of the Board of Directors.
"Sequoia is pleased to have recruited such an outstanding, talented
leader as Steven Skolsky," said Chris Mirabelli, Chairman of the Board of
Sequoia Pharmaceuticals. "Steve has an impressive record of success within
the pharmaceutical industry. The combination of his leadership and
management experience, as well as his business acumen, makes Steve uniquely
qualified to lead us through the exciting times ahead."
"Sequoia possesses an extraordinary scientific pedigree, and a very
attractive research portfolio. I am honored to have the opportunity to lead
Sequoia, and to build on its outstanding technological progress as we move
towards commercialization", said Mr. Skolsky.
Mr. Skolsky brings over twenty-five years of U.S. and international
experience in the pharmaceutical and biotechnology arena. He most recently
served as chief executive officer of Trimeris, a biotechnology company
specializing in HIV therapeutics. Previously Mr. Skolsky had a
distinguished career at GlaxoSmithKline where he served as GSK's Senior
Vice President of Global Commercial Strategy responsible for world-wide
clinical development and product strategy. He also served as managing
director of GSK's operations in Australia and New Zealand and previously
was Vice President of Sales and Marketing of the HIV/Oncology Division at
Glaxo Wellcome. He is a graduate of the University of North Carolina at
Chapel Hill.
About Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals discovers and develops revolutionary new
treatments, primarily for viral diseases including HIV/AIDS and HCV-induced
hepatitis. In addition, Sequoia has an active R&D program in
pharmacokinetic enhancers.
SOURCE Sequoia Pharmaceuticals, Inc.
Back to top
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
![]()
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All The Glitters: The Ultimate Gold Report".
